41 completed, 23 unknown, 7 recruiting, 6 terminated. 83 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 83 | Completed 41, Unknown 23, Recruiting 7, Terminated 6, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | AbbVie | 100 | 2025-07-24 | 2026-09-11 |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML Cladribine, Cytarabine, G-CSF - Relapsed/Refractory AML | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 172 | 2025-02-01 | 2025-01-08 |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 85 | 2024-11-28 | 2026-06-08 |
| Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality Oral Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | Virginia Commonwealth University | 12 | 2024-11-07 | 2026-05-29 |
| Antimicrobial Revision in Persistent Febrile Neutropenia Meropenem, Micafungin - Febrile Neutropenia | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2024-08-01 | 2024-09-19 | |
| RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR Venetoclax, Allogeneic transplant - Acute Myeloid Leukemia | Phase 4 | Recruiting | He Huang | 118 | 2024-07-17 | 2024-08-26 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy Venetoclax, Azacitidine, Decitabine - Acute Myeloid Leukemia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 24 | 2022-06-01 | 2026-08-21 |
| A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Flumatinib, Imatinib - CML, Chronic Phase | Phase 4 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2400 | 2022-04-30 | 2022-05-10 |
| Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). daunomycin/Idarubicin+ Silybinin, daunomycin/Idarubicin - Acute Myeloid Leukemia, Newly Diagnosed | Phase 4 | Recruiting | Fujian Medical University Union Hospital | 100 | 2022-04-01 | 2026-05-01 |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 4 | Active not recruiting | AbbVie | 44 | 2022-01-06 | 2025-08-12 |
| Ropeginterferon for Treatment Free Remission Ropeginterferon - CML (Chronic Myelogenous Leukemia) | Phase 4 | Completed | Dong-Wook Kim | 65 | 2021-11-30 | 2025-08-22 |
| A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg) - CML, Chronic Phase | Phase 4 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 200 | 2021-11-23 | 2022-04-29 |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 200 | 2021-01-01 | 2022-03-16 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| Ikervis for DED Due to GVHD Post Allo-HSCT Cyclosporine Ophthalmic - Leukemia (Both ALL and AML), MDS-EB-1 | Phase 4 | Unknown | Singapore Eye Research Institute | 40 | 2019-11-28 | 2020-11-19 |
| Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy Azacytidine, HAG Regimen, Azacytidine - Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia | Phase 4 | Unknown | Shenzhen Second People's Hospital | 114 | 2019-09-01 | 2022-03-15 |
| Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia Outpatient Care Model, CPX-351 - Leukemia, Myeloid, Acute | Phase 4 | Terminated | Medical College of Wisconsin | 3 | 2019-08-28 | 2022-07-19 |
Showing 20 of 83. Sign in to see all of them.
Leukemia, Myeloid, Acute (41) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29) · Leukemia (11) · Leukemia, Myeloid, Chronic-Phase (8) · Leukemia, Promyelocytic, Acute (7) · Myelodysplastic Syndromes (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Blast Crisis (3) · Bronchiolitis Obliterans Syndrome (3) · Recurrence (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Esophageal Neoplasms (2) · Febrile Neutropenia (2)
Hematologic Diseases (83) · Hemic and Lymphatic Diseases (83) · Neoplasms by Histologic Type (83) · Neoplasms (82) · Leukemia (72) · Bone Marrow Diseases (43) · Pathologic Processes (40) · Pathological Conditions, Signs and Symptoms (40) · Disease Attributes (38) · Chronic Disease (36) · Myeloproliferative Disorders (36) · Immune System Diseases (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Leukemia, Myeloid, Acute (6)
nilotinib (14) · Cytarabine (13) · Imatinib Mesylate (11) · Idarubicin (9) · Azacitidine (5) · Dasatinib (5) · fludarabine (5) · venetoclax (5) · Granulocyte Colony-Stimulating Factor (4) · Arsenic Trioxide (3) · Daunorubicin (3) · Decitabine (3) · Mitoxantrone (3) · posaconazole (3) · Cyclophosphamide (2)
Novartis Pharmaceuticals (16) · PETHEMA Foundation (8) · Technische Universität Dresden (4) · Shenzhen Second People's Hospital (3) · AbbVie (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire, Amiens (1) · Changhai Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Cttq (1) · Cytovia, Inc. (1) · Dong-A ST Co., Ltd. (1)
China (21) · United States (16) · Germany (13) · Spain (13) · France (9) · Canada (7) · Italy (7) · South Korea (7) · Poland (5) · India (4) · Russia (4) · Singapore (4) · Sweden (4) · United Kingdom (4) · Austria (3)
Sanz Miguel Angel, Dr (4) · Gerhard Ehninger, MD (3) · Jun Ma (2) · Xianmin Song, Doctor (2) · Alessandra Iurlo, MD (1) · Andreas Hochhaus, Professor, MD (1) · Arnon Nagler, MD (1) · Barry R. Meisenberg, MD (1) · Bruno Martino, MD (1) · Bueno Javier, Dr (1) · Carlo Gambacorti-Passerini, MD (1)
PMID 36064577, PMID 24923295, PMID 28945881, PMID 10231138, PMID 10583235, PMID 12627513, PMID 15770833, PMID 16110027, PMID 16197446, PMID 18056840, PMID 18398750, PMID 19720924, PMID 19822296, PMID 20220063, PMID 20393132, PMID 20442365, PMID 20542125, PMID 20625136, PMID 21148082, PMID 21266057, PMID 21670449, PMID 21775497, PMID 22197676, PMID 22241828, PMID 22290953, PMID 22318524, PMID 22512017, PMID 22871557, PMID 22965967, PMID 23317527, PMID 23376821, PMID 23630210, PMID 23733379, PMID 24117042, PMID 25170123, PMID 25314773, PMID 25528350, PMID 25547501, PMID 25975975, PMID 26863635, PMID 26993758, PMID 27771544, PMID 28235771, PMID 28529313, PMID 28584252, PMID 28721449, PMID 29250743, PMID 29577674, PMID 30076280, PMID 30315349
2014 (1), 2015 (1), 2023 (1), R01CA091912 (1)